Market closed·Syncing…
Market closed · Close · 19 Nov

Bafna Pharmaceuticals Limited BAFNAPHshare price and chart

Bafna Pharmaceuticals closed at ₹479.50 on 19 November 2026, up 1.93% on the day. The 52-week range is ₹94.77 to ₹501.65.

₹479.50The price one share last traded at, in rupees.+1.93% · ₹9.08
52-wk low ₹9595% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹502

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on BAFNAPH

Real prices, every charge counted. Pick one or write your own.
What Bafna Pharmaceuticals Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Bafna Pharmaceuticals, a 31-year-old company, develops, makes and exports finished medicines and is a contract research and manufacturing partner. It has 336 formulations across antibiotics, anti-infectives, supplements, cardiovascular, diabetes, nervous system and oncology, exported to more than 20 countries.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Generic formulations, contract research and manufacturing

3
3Who buys it

Regulated and emerging export markets, pharmaceutical partners

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
63.7Neutral
0 oversold3070overbought 100
vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+17.5%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+107.7%1 monthHow much the share price has changed over the period.+4.0%3 monthsHow much the share price has changed over the period.+97.7%1 yearHow much the share price has changed over the period.+159.4%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.29.7%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹1,134 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.98.7xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.12.3%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.10.99xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.11.9%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.56.5xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.36xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-6.3%year to Mar 2026

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 11 Nov 2026), sales rose 34.4% from a year earlier to ₹47.7 cr and profit rose 119.1% to ₹6.8 cr.

Going well
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
  • No promoter shares were pledged at the end of September 2026.
Worth watching
  • Promoter holding fell 13.3 points over 8 quarters (88.30% to 75.00%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 20 results, the share rose on 10 and fell on 10, and moved by 3% or more on 12.

+9%
-9%
Q2 FY23Q2 FY24Q2 FY25Q2 FY26Q2 FY27

Q2 FY27: results filed 11 Nov 2026. The share went from its close on 9 Nov 2026 to its close on 12 Nov 2026 +4.03%.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+29.9%a year, over 5 years
1 yr
+181.2%
3 yr
+78.9%
5 yr
+29.9%

Held for 5 years this compounded at +29.9% a year. The last twelve months were up +181.2%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
75%promoter holding, as of 2026-09-30-15.4 pts since 2021
Promoter share since listing
2021-0975% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
75.0%
15.7%
Promoter75.0%Foreign (FII)9.3%Public & others15.7%
Who is buying, who is leavingJun 25 to Sep 26
Promoter75.0%steady
Foreign (FII)9.3%steady
Domestic (DII)
-

Each line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.0.00%of promoter shares, as at 2026-09-30

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Copy of Newspaper Publication16-Nov-2026

Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter & Half Year ended September 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on November 13, 2026.

Outcome of Board Meeting11-Nov-2026

Bafna Pharmaceuticals Limited has submitted to the Exchange, the Outcome of the Board Meeting held on 11/11/2026 along with the Unaudited Financial Results and Limited Review Report issued by the Statutory Auditors, for the Quarter and Half Year ended September 30, 2026.

Certificate under SEBI (Depositories and Participants) Regulations, 201812-Oct-2026

Bafna Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026

Trading Window26-Sep-2026

Bafna Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Shareholders meeting11-Sep-2026

Bafna Pharmaceuticals Limited has submitted to the Exchange Voting Results of the 31st Annual General Meeting of the Company held on September 11, 2026 along with the Scrutinizer Report.

Shareholders meeting11-Sep-2026

Bafna Pharmaceuticals Limited has informed the Exchange regarding Proceedings of the 31st Annual General Meeting of the Company held on September 11, 2026

Copy of Newspaper Publication21-Aug-2026

Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, 2026

Shareholders meeting19-Aug-2026

Bafna Pharmaceuticals Limited has informed the Exchange regarding Notice of 31st Annual General Meeting of the Company to be held on September 11, 2026 along with the Annual Report for F.Y 2025-2026

Copy of Newspaper Publication14-Aug-2026

Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026

Updates13-Aug-2026

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for Book Closure & Cut off Date'.

Shareholders meeting13-Aug-2026

Bafna Pharmaceuticals Limited has informed the Exchange regarding intimation for 31st Annual General Meeting of the Company to be held on September 11, 2026

Outcome of Board Meeting11-Aug-2026

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 11, 2026.

Outcome of Board Meeting11-Aug-2026

Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on 11/08/2026 along with the unaudited financial results for the quarter ended June 30, 2026.

Certificate under SEBI (Depositories and Participants) Regulations, 201809-Jul-2026

Bafna Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Disclosure under SEBI Takeover Regulations30-Jun-2026

Bafna Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Backtest idea · BAFNAPHMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on BAFNAPH
Backtest idea · BAFNAPHLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on BAFNAPH
Backtest idea · BAFNAPHSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on BAFNAPH
Your own ideaWrite a rule for BAFNAPH in plain English“Buy BAFNAPH when …”
Start writing
Buy the dip on BAFNAPHBuy when RSI(14) drops below 30
52-week high breakout on BAFNAPHBuy when closes at a 52-week high
Golden cross on BAFNAPHBuy when 50-day EMA crosses above 200-day
Stochastic oversold on BAFNAPHBuy when stochastic %K drops below 20
Pullback in an uptrend on BAFNAPHBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹1,134 cr
No sector comparison yet
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
98.7x
No sector comparison yet
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
11.0x
No sector comparison yet
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
12.3%
No sector comparison yet
FY23 15.4%FY26 12.3%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
11.9%
No sector comparison yet
FY23 14.2%FY26 11.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.36
No sector comparison yet
FY23 0.31FY26 0.39
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
No sector comparison yet
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+34.4%
No sector comparison yet
FY23 35.5%FY26 3.2%

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.10.6%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+119.2%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹151 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹11 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹7.4 as profit. Other income added ₹3.2.

Where it wentPer ₹100 of sales
Running costs₹89.4Depreciation₹4.1Interest₹2.5Profit₹7.4
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+9.3%-+34.4%
Profit▼ 0.6%-+119.2%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹1 Cr, after ₹25 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹15 Cr
Investing-₹22 Cr
Lenders and shareholders+₹6 Cr
Net change in cash-₹1 Cr
Operating cash per ₹100 of profit
₹44FY23₹129FY24₹533FY25₹138FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.35.5%32.3%-4.3%3.2%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.13.3%7.3%7.7%10.6%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.9.8%4.8%2.9%7.4%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.15.4%9.5%5.0%12.3%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.14.2%9.6%6.3%11.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.31x0.30x0.33x0.39x
Interest coverHow many times the company's profit before interest could pay its interest bill.6.8x4.2x2.6x4.0x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · BAFNAPHStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on BAFNAPH
Backtest idea · BAFNAPHPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on BAFNAPH
Backtest idea · BAFNAPHBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on BAFNAPH
Backtest idea · BAFNAPH52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on BAFNAPH
Backtest idea · BAFNAPHGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on BAFNAPH
MACD momentum on BAFNAPHBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on BAFNAPHBuy when closes below the lower Bollinger band
Supertrend rider on BAFNAPHBuy when supertrend turns up
Buy the dip on BAFNAPHBuy when RSI(14) drops below 30
52-week high breakout on BAFNAPHBuy when closes at a 52-week high

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-26.0
-4.9
+3.0
+22.6
-1.6
+62.7
+22.5
+15.7
+22.1
+20.6
+7.1
·
+218.1%
11m
2025
+1.4
-8.0
+1.6
+6.8
-6.1
+12.1
+4.0
+18.8
+69.7
-18.5
+5.3
-0.4
+91.0%
2024
+6.5
-10.7
-10.5
+21.0
-5.1
-16.1
+13.9
-6.2
+5.3
-7.6
+1.8
-1.4
-14.3%
2023
-2.2
-2.6
-14.5
-1.3
+32.9
-0.8
-14.7
+12.5
-18.5
+3.2
+1.7
+4.9
-8.7%
2022
-8.2
-13.6
+4.7
+7.0
-17.6
+3.0
-5.3
+5.4
-11.2
-0.8
+0.5
-0.8
-33.9%
2021
-27.3
-0.2
+10.8
-4.8
+2.8
+4.7
+9.3
-13.5
-3.5
-5.2
-3.8
+30.2
-10.7%
2020
·
·
·
+53.0
+0.0
+10.1
+0.0
+4.9
+77.7
+176.4
+16.0
+27.6
+1184.6%
9m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-08-06M7 GLOBAL FUND PCC-AERION · bulkSELL6,66,000₹284.55₹18.95 Cr
2026-08-06CULLINAN OPPRTS FUND VCC-CULLINAN OPPORTUNITIES INCORPORATED VCC SUB FUND 1 · bulkBUY6,66,000₹284.55₹18.95 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test BAFNAPH. “Buy BAFNAPH when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free